How to Play Moderna Stock After the Recent Sales Guidance Cut

On Monday, Moderna (MRNA) provided an update on its financial outlook and pipeline progress at the J.P. Morgan Healthcare Conference. At the conference, the company lowered its previously issued sales outlook for 2024 and 2025.Moderna reported unaudited/preliminary product sales between $3 billion and$3.1 billion for 2024, toward the lower end of its previously issued guidance of $3.0-$3.5 billion. MRNA also reduced its previously announced sales guidance for 2025 by $1 billion and now expects total revenu ...